Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT
Authors:
- Meritxell MollaMMMeritxell Molla
- Julen Fernandez-PlanaJFJulen Fernandez-Plana
- Santiago AlbiolSASantiago Albiol
- Constantino FondevilaCFConstantino Fondevila
- Ivan VollmerIVIvan Vollmer
- Carla CasesCCCarla Cases
- Angeles Garcia-CriadoAGAngeles Garcia-Criado
- Jaume CapdevilaJCJaume Capdevila
- Carles ConillCCCarles Conill
- Yliam FundoraYFYliam Fundora
- Carlos Fernandez-MartosCFCarlos Fernandez-Martos
- Estela PinedaEPEstela Pineda
Open Access
- 14 May 2021
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2131
Abstract
The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy (SBRT). There are several factors to consider when deciding on the better approach for each patient: tumor factors (metachronous or synchronous metastases, RAS mutation, BRAF mutation, disease-free interval, size and number of metastases), patient factors (age, frailty, comorbidities, patient preferences), and physicians’ factors (local expertise). These advances have presented major challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases from colorectal cancer with a curative intention. In this review, we describe the different treatment options in patients with limited liver and lung metastases from colorectal cancer, and the possible combination of three approaches: systemic treatment, surgery, and local ablative treatments.Keywords
This publication has 65 references indexed in Scilit:
- Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited MetastasesJournal of Clinical Oncology, 2013
- Stereotactic body radiotherapy for oligometastasesThe Lancet Oncology, 2013
- Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal CancerJournal of Clinical Oncology, 2011
- Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trialBritish Journal of Cancer, 2010
- A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatmentBMC Cancer, 2010
- Reported Outcome Factors for Pulmonary Resection in Metastatic Colorectal CancerJournal of Thoracic Oncology, 2010
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialThe Lancet Oncology, 2010
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008
- Percutaneous Radiofrequency Ablation of Pulmonary Metastases from Colorectal Carcinoma: Prognostic Determinants for SurvivalAnnals of Surgical Oncology, 2006
- Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by ChemotherapyAnnals of Surgery, 2004